glp 1 agonist and blindness From metabolism to mind: The expanding role of the GLP-1 receptor in neurotherapeutics The current significance and prospects

Obesity and type 2 diabetes remain critical global health challenges, with rising prevalence demanding innovative treatment approaches

Primary care physicians often make decisions regarding the initiation of basal insulin in T2D, as they work closely with patients and are well placed to discuss and manage the transition to basal insulin therapy

Over the last year, the Indian obesity-treatment market has changed very fast

Additionally, these are not components of FDA-approved drugs and have not been found safe and effective for any condition.At this time, these drugs are only legally accessible to clinical trial patients

DPP-4 inhibitors were introduced for the treatment of type 2 diabetes in 2006

Tirzepatide, a novel twincretin drug, significantly improves weight loss and glycemic control in obese and type 2 diabetes patients, outperforming traditional treatments in clinical trials.